YONG LI to Mutation
This is a "connection" page, showing publications YONG LI has written about Mutation.
Connection Strength
0.839
-
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant. J Hematol Oncol. 2024 06 18; 17(1):45.
Score: 0.322
-
Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci. 2020 Jun 08; 21(11).
Score: 0.244
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
Score: 0.085
-
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2023 04 11; 7(7):1308-1311.
Score: 0.074
-
MYD88 L265P elicits mutation-specific ubiquitination to drive NF-?B activation and lymphomagenesis. Blood. 2021 03 25; 137(12):1615-1627.
Score: 0.064
-
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. Oncoimmunology. 2024; 13(1):2384667.
Score: 0.020
-
Abnormal X chromosome inactivation and tumor development. Cell Mol Life Sci. 2020 Aug; 77(15):2949-2958.
Score: 0.015
-
Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019 08 23; 18(1):128.
Score: 0.014